Replies to post #81918 on Anavex Life Sciences Corp (AVXL)

[sokol]

Dose optimization: I remember that Missling said that the AVXL 2-73 was yet to be optimized. This factor could result in improved results in the future trial assuming safety is maintained with increased dosage. I am interested in knowing more about this and perhaps other things that have been learned to improve benefits -- besides mono-therapy?

[scratchy]

They had this at 6 months but couldn't show it in enough Data,,
Why they brought on Ariana.

I beleive this is the case as well. Something is so different in the results they wanted confirmation from robust analysis.

[tredenwater2]

I agree MC. The fact that the graphs at 31 weeks showed improvement but management didn't support it is what confused shareholders and the "market". The line was there but no data! I believe its through additional time, Ariana and an improving graph has bolstered confidence by actually giving the FDA, Management, and possibly Dr. Perry the PROOF they needed. They see the patients getting better , they just couldn't prove it clinically yet.
Question, with two extensions why are patients still not on optimized dosage yet.
Optimistic that our CEO is going to fire MISSLING MISSLES at the market come Monday Dec. 12th.

locked and loaded

Tred